This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It provides tailored legal and regulatory support to patients, researchers, businesses, and incubators, driving progress in healthcare and biotechnology. Another main study in this key area involves the study of biotechnologies and so-called biosolutions. We recently published a study for the European Commission on these issues.
What You Should Know: Range Biotechnologies (Range Bio) announced $5.2M Thus, developing more effective ways to diagnose, treat, and prevent diseases such as cardiovascular disease, cancer, COPD, MS, and more. Proteomics, the study of proteins in the body, has the potential to improve human health in several ways.
What You Should Know: – ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The CorriXR Therapeutics team includes experienced biotechnology executives and world-renowned scientists and clinicians. The executive team is led by Eric Kmiec, Ph.D.,
Co-Founder, President, & CEO of Obatala Sciences, Inc. These solutions, provided to pharmaceutical companies, government labs, and researchers, are designed to accelerate the study and prevention of diseases in the fields of obesity, diabetes, cancer, and regenerative medicines. Trivia Frazier, Ph.D.,
What You Should Know: – clock.bio , a healthspan biotechnology company based at the Milner Therapeutics Institute in Cambridge, has secured $5.3M A Vision for Increased Healthspan clock.bio’s mission is to increase human healthspan by developing treatments that prevent and treat age-related diseases.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
Freenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw. will help LHN members bring innovative cancer prevention testing to the communities they serve. A Comprehensive Multiomics Platform for the Early Detection of Cancer. Trial participation?will
In recent decades, advancements in biotechnology have made it possible to develop synthetic nuclei. The binding of an antibody to its antigen initiates a detailed immune response aimed at a particular pathogen and helps prevent infection. This binding helps eliminate the pathogens without harming the body’s cells.
Sonia Fischer, Customer Integrations Manager, IQVIA In the age of biotechnology , biosample collection has become an essential part of medical research. The extra effort may require a greater initial investment, but it could potentially prevent the need to recruit additional patients.
Biovac will become the first African producer of IPV, directly contributing to the continent’s goal of producing 60% of its vaccines locally by 2040, as envisioned by the Africa Centers for Disease Control and Prevention. Sanofi’s Legacy of Polio Eradication Sanofi boasts a long-standing commitment to polio eradication.
Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. What You Should Know: – Nectin Therapeutics Ltd.,
Ivor Campbell, CEO of Snedden Campbell The global landscape for medical technology, biotechnology, and lifesciences is on the cusp of seismic change. The broad lifescience industry too is in the midst of a period of significant transition.
We organize all of the trending information in your field so you don't have to. Join 19,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content